TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06563882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06216288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated back extension exercise (McKenzie)
Description: repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
Study: NCT04750512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
Study: NCT05453955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Study: NCT06216288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated back extension exercise (McKenzie)
Description: repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
Study: NCT05453955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Study: NCT04697576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: immune checkpoint inhibitor
Study: NCT06563245

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
Study: NCT04697576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: immune checkpoint inhibitor
Study: NCT06563245

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25mg/m2/dose,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25mg/m2/dose,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25mg/m2/dose,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 125 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 125 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 125 mg/m2/dose
Study: NCT06216288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical traction
Description: The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
Study: NCT04750512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle.
Study: NCT06564233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care.coach Avatar™
Description: care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings.
Study: NCT06400082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
Study: NCT05298930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges.
Study: NCT06638411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHD information workshop
Description: ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADHD information workshop with nocebo education
Description: ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep workshop
Description: An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
Study: NCT05851963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonicare Diamond Clean 9000
Description: Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HydroSonic Pro
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Oral-B 123
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curaprox CS 5460
Description: Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
Study: NCT04961593

Intervention type: DRUG
Intervention: Caspofungin
Description: For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
Study: NCT06564545

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT04697576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: immune checkpoint inhibitor
Study: NCT06563245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg/m2, BID, orally
Study: NCT06362798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Transfers
Description: Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age.
Study: NCT06563245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg/m2, BID, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 20 mg/m2, BID, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: 3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: 3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedamustine
Description: 180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedamustine
Description: 180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Study: NCT05632692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol solution
Description: Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Menthol solution
Description: Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
Study: NCT06331117

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: Multiomics profiling
Study: NCT04697576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: immune checkpoint inhibitor
Study: NCT04906330

Intervention type: DIAGNOSTIC_TEST
Intervention: Oncoliq: test for early breast cancer detection.
Description: Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
Study: NCT06461117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Beetroot juice (8 mmol NO3-) consumption before training at 6 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plesabo Drink
Description: Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
Study: NCT05687682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM-928
Description: AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
Study: NCT04922450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous administration of SHR1210 (200mg/3weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel(260mg/m²),every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin（80mg/m²）, every 3 weeks
Study: NCT06060548

Intervention type: OTHER
Intervention: Monitoring of patients presenting with PVCs
Description: Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
Study: NCT05443906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Exercise to address limitations impacting walking
Study: NCT06044792

Intervention type: OTHER
Intervention: differences in CD4 reconstruction
Description: Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.

Intervention type: OTHER
Intervention: differences in CD4 reconstruction
Description: Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
Study: NCT06166264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The participants will receive information regarding health education.
Study: NCT06472544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Grounded Intervention
Description: Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
Study: NCT05193318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-assisted psychotherapy
Description: Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
Study: NCT04311307

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: [6,6-2H2]glucose
Description: Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [6,6-2H2]glucose
Description: Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
Study: NCT05910346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and counseling based on maternal role theory
Description: Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.